Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
Withdrawn before enrolling · Phase 2
Conditions studied: Pulmonary Hypertension
In brief
The purpose of this study is to determine the safety and maximum tolerated dose of inhaled NX1011 for the treatment of pulmonary arterial hypertension (PAH).
Key facts
- Study ID
- NCT00323024
- Run by
- NITROX, LLC
- People needed
- 72
- Starts
- 2006-09-01
- Expected to finish
- 2007-05-01
- Last updated by the study team
- 2007-08-30
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient must either:
- meet the PAH diagnostic criteria at Screening (based on a documented history of diagnosis as outlined in the American College of Chest Physicians [ACCP] 2004 Evidence-Based Clinical Practices Guidelines)15; or
- have elevated pulmonary pressure with a suspected PAH diagnosis based on a clinical referral at Screening for a RHC.
- Patient must have PAH as defined by a mean pulmonary artery pressure (PAP) > 25 mmHg.
- Patient must have symptoms of pulmonary hypertension (PH) according to the World Health Organization (WHO) Functional Classification of Pulmonary Hypertension Class II through IV.
- Patient must consent to, be able to tolerate, and have adequate venous and arterial access for Swan-Ganz catheterization (SGC) and an arterial line.
You may not qualify if…
- Clinically significant right-to-left intracardiac shunts based on Doppler echocardiography with bubble study.
- History of pulmonary veno-occlusive disease or clinically significant aortic or mitral stenosis.
- History of sustained ventricular tachycardia (VT-S) or ventricular fibrillation (VF) and cardiac arrest, or presence of atrial fibrillation.
- Active cardiac disease meeting the following criteria:
- Patient with elevated pulmonary capillary wedge pressures (PCWPs) > 25 mmHg.
- Patient with a history of myocardial infarction or coronary intervention within the last 60 days.
- Patient with a history of pacemaker, cardiac defibrillator, or biventricular pacemaker insertion within 4 weeks of Baseline.
- Patient who cannot be withdrawn from nitrate therapy.
Where it is running
- Arizona Pulmonary Specialists, Ltd. — Phoenix, Arizona, United States
- University of California, San Diego Medical Center — La Jolla, California, United States
- Christiana Care Health Services — Newark, Delaware, United States
- University of Maryland — Baltimore, Maryland, United States
- Brigham and Women's Hospital — Boston, Massachusetts, United States
- University of Michigan Medical Center — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.